135 related articles for article (PubMed ID: 21856102)
1. Contrast media safety-an update.
Thomsen HS
Eur J Radiol; 2011 Oct; 80(1):77-82. PubMed ID: 21856102
[TBL] [Abstract][Full Text] [Related]
2. [Guidelines for administering gadolinium-based contrast agents to patients with renal dysfunction--second edition].
Hosoya T; Okada H; Horio M; Ohno I; Tamura S; Sugimoto H; Tsushima Y; Hayashi H; Fukuda K; Korogi Y; Yoshifumi N
Nihon Jinzo Gakkai Shi; 2009; 51(7):839-42. PubMed ID: 19928554
[No Abstract] [Full Text] [Related]
3. Nephrogenic systemic fibrosis and gadolinium-based contrast agents.
Abu-Alfa AK
Adv Chronic Kidney Dis; 2011 May; 18(3):188-98. PubMed ID: 21531325
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of NSF following intravenous gadolinium-contrast media administration in dialysis patients with endstage renal disease.
Heinz-Peer G; Neruda A; Watschinger B; Vychytil A; Geusau A; Haumer M; Weber M
Eur J Radiol; 2010 Oct; 76(1):129-34. PubMed ID: 19619969
[TBL] [Abstract][Full Text] [Related]
5. Gadolinium-associated nephrogenic systemic fibrosis.
Schlaudecker JD; Bernheisel CR
Am Fam Physician; 2009 Oct; 80(7):711-4. PubMed ID: 19817341
[TBL] [Abstract][Full Text] [Related]
6. [Gadolinium-based contrast agents for magnetic resonance imaging].
Carrasco Muñoz S; Calles Blanco C; Marcin J; Fernández Álvarez C; Lafuente Martínez J
Radiologia; 2014 Jun; 56 Suppl 1():21-8. PubMed ID: 25304299
[TBL] [Abstract][Full Text] [Related]
7. Nephrogenic systemic fibrosis and management of high-risk patients.
Altun E; Semelka RC; Cakit C
Acad Radiol; 2009 Jul; 16(7):897-905. PubMed ID: 19375360
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis.
Weinreb JC; Kuo PH
Magn Reson Imaging Clin N Am; 2009 Feb; 17(1):159-67. PubMed ID: 19364606
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis and the role of gadolinium contrast media.
van der Molen AJ
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):339-50. PubMed ID: 18811757
[TBL] [Abstract][Full Text] [Related]
10. Nephrogenic systemic fibrosis and gadolinium-enhanced magnetic resonance imaging: does a US Food and Drug Administration alert influence practice patterns in CKD?
Martin DR
Am J Kidney Dis; 2010 Sep; 56(3):427-30. PubMed ID: 20728788
[No Abstract] [Full Text] [Related]
11. Nephrogenic systemic fibrosis developed after recovery from acute renal failure: gadolinium as a possible aetiological factor.
Lu CF; Hsiao CH; Tjiu JW
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):339-40. PubMed ID: 18573157
[No Abstract] [Full Text] [Related]
12. Current status of gadolinium toxicity in patients with kidney disease.
Perazella MA
Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
[TBL] [Abstract][Full Text] [Related]
13. Contrast-induced nephropathy and nephrogenic systemic fibrosis. Preface.
Morcos SK
Radiol Clin North Am; 2009 Sep; 47(5):xi. PubMed ID: 19744592
[No Abstract] [Full Text] [Related]
14. Nephrogenic systemic fibrosis and contrast medium-induced nephropathy: a choice between the devil and the deep blue sea for patients with reduced renal function?
Lind Ramskov K; Thomsen HS
Acta Radiol; 2009 Nov; 50(9):965-7. PubMed ID: 19863403
[No Abstract] [Full Text] [Related]
15. MRI contrast media: what clinicians need to know.
Das CJ; Mahalingam S; Debnath J; Dhawan S
Natl Med J India; 2010; 23(5):292-6. PubMed ID: 21250587
[TBL] [Abstract][Full Text] [Related]
16. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
17. A review of preclinical safety data for magnevist (gadopentetate dimeglumine) in the context of nephrogenic systemic fibrosis.
Steger-Hartmann T; Hofmeister R; Ernst R; Pietsch H; Sieber MA; Walter J
Invest Radiol; 2010 Sep; 45(9):520-8. PubMed ID: 20644486
[TBL] [Abstract][Full Text] [Related]
18. Toxicity of contrast media: an update.
ten Dam MA; Wetzels JF
Neth J Med; 2008 Nov; 66(10):416-22. PubMed ID: 19011267
[TBL] [Abstract][Full Text] [Related]
19. Renal failure and gadolinium. The number of documented cases is rising.
Prescrire Int; 2008 Oct; 17(97):205. PubMed ID: 19537311
[No Abstract] [Full Text] [Related]
20. Nephrogenic systemic fibrosis and gadolinium: a cautionary tale in the molecular imaging era.
Wang SC
J Med Imaging Radiat Oncol; 2008 Aug; 52(4):305-6. PubMed ID: 18811752
[No Abstract] [Full Text] [Related]
[Next] [New Search]
